

Embecta Corp. Class Action Lawsuit

U.S. Securities Litigation

Embecta Complaint Overview

The Embecta class action lawsuit asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Embecta common stock. The class action is pending in the U.S. District Court for the District of New Jersey. It is captioned *Apitz-Grossman v. Embecta Corp., et al.*, No. 26-cv-07217.

If you lost money on your Embecta investment, you are encouraged to submit your information using the form on this page. You may also email adam@bfalaw.com or call 212.789.3619.

Why is Embecta Being Sued for Securities Fraud?

Embecta has been sued for securities fraud following a significant stock drop resulting from potential violations of the federal securities laws. The decline in Embecta's stock price caused significant losses to investors.

Embecta is a medical device company that produces insulin pens for patients with diabetes. According to the complaint, during the relevant period, Embecta touted the strength of its insulin pen portfolio stating that "prescriptions for insulin pens have been showing a slight positive trend . . . just exemplifying the resilience of this product portfolio."

As alleged, in truth, Embecta faced significant competition and "overall market softness for insulin pens and pen needles."

Why did Embecta's Stock Drop?

On May 5, 2026, Embecta announced disappointing Q2 2026 results that came in below guidance due to share loss within its pen needle product category, most of which was from a single customer. Embecta also reported an "overall market volume softness for insulin pens and pen needles in the retail channel," admitting that "we have now begun to see a decline [for insulin pens] maybe more

pronounced in the most recent quarter that we reported.” As a result, Embecta also reduced its quarterly dividend from \$0.15 to \$0.01 per share. This news caused the price of Embecta common stock to decline \$5.35 per share, or 57.8%, from \$9.25 per share on May 4, 2026, to \$3.90 per share on May 5, 2026.

What is the Embecta Leadership Deadline?

You may ask the Court no later than August 17, 2026, to appoint you as Lead Plaintiff through counsel of your choice.

To be a member of the Class, you need not take any action at this time. The ability to share in any potential future recovery is not dependent on serving as Lead Plaintiff.

How Do I Submit My Information?

If you lost money when Embecta common stock dropped in price, you are encouraged to submit your information using the form on this page to speak with an attorney about your rights.

You can also contact:

Adam McCall
amccall@bfalaw.com
212.789.3619

All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of any class action lawsuit. The firm will seek court approval for any potential fees and expenses.

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by *Chambers USA*, *The Legal 500*, and *ISS SCAS*.

BFA attorneys have been named “Elite Trial Lawyers” by the *National Law Journal*, “Litigation Stars” by *Benchmark Litigation*, among the top “500 Leading Plaintiff

Financial Lawyers” by *Lawdragon*, “Titans of the Plaintiffs’ Bar” by *Law360*, and “SuperLawyers” by *Thomson Reuters*.

Most recently, *The Legal 500* awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”

Among its recent notable successes, BFA recovered over \$900 million in value from Tesla, Inc.’s Board of Directors, as well as \$420 million from Teva Pharmaceutical Ind. Ltd.

Attorney advertising. Past results do not guarantee future outcomes.